Various guidelines of different countries, e.g. those from the UK1, Germany2, France or from the ECCO3, exist for the management of Crohn's disease (CD). The recent European evidence-based consensus on the diagnosis and management of CD3 defines mildly active CD by a CDAI of 150-220 points and moderately active CD by a CDAI of 220-450 points. For the treatment of mildly active ileocaecal CD the consensus recommended budesonide 9 mg/day as the preferred treatment. The consensus stated that the benefit of mesalazine is limited. Antibiotics are not recommended. No treatment is an option for some patients with mild symptoms. Moderately active ileocaecal CD should preferably be treated with budesonide 9 mg/day or with systemic corticosteroids. Antibiotics should be added if septic complications are suspected.
展开▼
